Trial Profile
A Single Centre, Open-label Study With Healthy Adult Volunteers to Determine the Effects of Single-dose and Steady-state TPV/r 500/200 mg on the Steady-state Pharmacokinetics of Carbamazepine (200 mg Twice Daily)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2014
Price :
$35
*
At a glance
- Drugs Tipranavir (Primary) ; Carbamazepine; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 08 Oct 2014 New trial record